:

NOVARTIS CEO JOINS ANTHROPIC BOARD

AI DESK1 MIN READ
WED, APR 15, 2026

■ AI-SUMMARIZED FROM 2 SOURCES ▸ TIMELINE

Anthropic announced that Novartis CEO Vas Narasimhan has joined its board of directors. The appointment signals the AI company's deepening commitment to healthcare and life sciences applications.

Narasimhan's addition to Anthropic's board comes as the Claude chatbot maker expands its presence in the pharmaceutical and biotech sectors. Earlier this month, Anthropic acquired biotech startup Coefficient Bio for approximately $400 million. The move reflects growing interest from major healthcare companies in artificial intelligence capabilities. Narasimhan brings decades of experience in pharmaceutical leadership and drug development, positioning him to guide Anthropic's healthcare initiatives. Anthhropic has been building specialized tools for life sciences research, leveraging Claude's language capabilities for tasks including drug discovery support and scientific analysis. The Coefficient Bio acquisition accelerated these efforts by bringing in specialized biotech expertise. Board appointments from pharmaceutical executives represent a significant vote of confidence from the healthcare industry in Anthropic's technology and direction. The partnership may also facilitate future collaborations between Anthropic and Novartis on AI applications in drug development and healthcare.

■ SOURCES

PlatformerPlatformer

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE AI DESK

Z.ai released GLM-5.3's weights on Hugging Face under a new license that requires large companies to undergo security review before hosting the model. The change marks a departure from the standard MIT license.

JUST NOWAI Desk

Anthropic has introduced the Model Hardware Standard (MHS), a unified interface enabling AI agents to operate robotic arms, lab instruments, and other physical devices. Early testing shows integration time has dropped from weeks to hours.

JUST NOWAI Desk

Open-weight AI companies—those releasing freely available models—are attracting major acquisition interest from tech giants. The trend reflects growing capital investment in the business model of distributing AI models at no cost.

2H AGOAI Desk

Google Deepmind has upgraded its Co-Scientist AI system to autonomously plan experiments, operate lab equipment, and publish scientific papers. The Gemini-based multi-agent platform demonstrated experimentally validated results across materials science, chemistry, and medical AI development.

2H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.